Astrazeneca (AZN) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Astrazeneca (NYSE: AZN) recently:

• 5/4/2026 – Astrazeneca had its “buy” rating reaffirmed by Sanford C. Bernstein.
• 5/2/2026 – Astrazeneca was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/30/2026 – Astrazeneca had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 4/30/2026 – Astrazeneca had its “sell” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 4/29/2026 – Astrazeneca was upgraded by Barclays PLC from “neutral” to “buy”.
• 4/29/2026 – Astrazeneca was upgraded by DZ Bank AG from “neutral” to “buy”.
• 4/23/2026 – Astrazeneca had its “buy” rating reaffirmed by JPMorgan Chase & Co..
• 4/10/2026 – Astrazeneca had its “buy” rating reaffirmed by UBS Group AG.
• 4/8/2026 – Astrazeneca had its “overweight” rating reaffirmed by Morgan Stanley.
• 4/4/2026 – Astrazeneca was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/20/2026 – Astrazeneca was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/18/2026 – Astrazeneca had its “buy” rating reaffirmed by TD Cowen.
• 3/12/2026 – Astrazeneca was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/11/2026 – Astrazeneca is now covered by Weiss Ratings. They set a “buy (b)” rating on the stock.

Astrazeneca Announces Dividend

The company also recently announced a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were paid a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio is 73.43%.

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.